Novel insights into the systemic treatment of lung cancer malignant pleural effusion
AbstractLung cancer is the most common fatal malignancy worldwide. Approximately 75% of non ‐small‐cell lung cancer (NSCLC) patients are diagnosed at an advanced or a metastatic stage. Since 2007, NSCLC patients with malignant pleural effusion (MPE) are staged as M1 disease. During the last decades, chemotherapeutic agents failed to offer a significant improvement of survival in patien ts with metastatic disease. The current review aims to summarize the actual situation of the recently developed therapies in patients with lung cancer and MPE.
Source: The Clinical Respiratory Journal - Category: Respiratory Medicine Authors: Claire Tissot,
Pierre Gay,
Cl ément Brun,
Marios E. Froudarakis Tags: SERIES ON PLEURAL DISEASES Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Men | Non-Small Cell Lung Cancer | Respiratory Medicine